《原发性肝癌诊疗指南(2022年版)》更新要点解读

Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer(2022 Edition)

自《原发性肝癌诊疗规范(2019年版)》发布以来,国内外在肝癌诊治领域涌现出许多新的循证医学高级别证据,尤其是多项符合中国肝癌患者诊疗的研究成果相继发表。为进一步规范我国肝癌诊疗行为,国家卫生健康委员会组织全国肝癌领域的多学科专家,更新并发布了《原发性肝癌诊疗指南(2022年版)》,旨在实现《“健康中国2030”规划纲要》提出的2030年总体癌症5年生存率提高15%的目标。本文将对2022年版指南的主要更新要点进行解读,以期推动新版指南的广泛传播与实施。

Since the publication of the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer(2019 Edition),many new high-level evidence in line with evidence-based medicine has emerged in the diagnosis and treatment of liver cancer at home and abroad,especially,a number of research results in line with Chinese liver cancer patients have been published.In order to further standardize the diagnosis and treatment of liver cancer in China,the National Health Commission organized multidisciplinary experts in the field of liver cancer to revise and update the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer(2022 Edition),aiming to increase the overall cancer 5-year survival rate by 15%,a goal mentioned in the“Healthy China 2030”Planning Outline.We interpret the main update points of the 2022 version,with the hope of promoting the widespread discussion and dissemination of the new version.